TG Therapeutics Files 8-K for Financial Update

Ticker: TGTX · Form: 8-K · Filed: Feb 28, 2024 · CIK: 1001316

Sentiment: neutral

Topics: 8-K Filing, Financial Update, Regulatory Filing

TL;DR

**TG Therapeutics filed an 8-K on Feb 28, signaling a financial update, but the actual numbers aren't in this snippet.**

AI Summary

TG Therapeutics, Inc. (CIK: 0001001316) filed an 8-K on February 28, 2024, reporting an event on the same date. This filing indicates the company is providing information related to its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. However, the provided text only contains the header information and does not include specific financial figures or detailed operational results.

Why It Matters

This 8-K signals that TG Therapeutics, Inc. is providing an update on its financial condition and results of operations, which is crucial for investors to understand the company's performance. Without the actual content, its immediate impact is limited to signaling an upcoming or concurrent disclosure.

Risk Assessment

Risk Level: medium — The provided text is only header information for an 8-K, not the substantive financial details, thus no specific financial risks can be identified from this snippet.

Key Players & Entities

FAQ

What is the exact name of the registrant for this 8-K filing?

The exact name of the registrant is TG Therapeutics, Inc.

What is the earliest event reported date for this 8-K?

The earliest event reported date for this 8-K is February 28, 2024.

What items of information are included in this 8-K filing according to the ITEM INFORMATION section?

The ITEM INFORMATION section indicates "Results of Operations and Financial Condition" and "Financial Statements and Exhibits."

What is the Central Index Key (CIK) for TG Therapeutics, Inc.?

The Central Index Key (CIK) for TG Therapeutics, Inc. is 0001001316.

In which state is TG Therapeutics, Inc. incorporated?

TG Therapeutics, Inc. is incorporated in Delaware.

Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-02-28 07:24:56

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 28, 2024, TG Therapeutics, Inc. (the "Company") issued a press release announcing results of operations for the three and twelve months ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated February 28, 2024. Exhibit 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TG THERAPEUTICS, INC. (Registrant) Date: February 28, 2024 By: /s/ Sean A. Power Name: Sean A. Power Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing